1. McLaughlin P, Cabanillas F, Newland AC (1991). Controversies in therapy for the low grade lymphomas. In Newland A, Burnett A, Keating A, Armitage J (eds), Haematological Oncology, vol. I. New York: Cambridge University Press, pp. 173–193.
2. Robertson LE, Keating MJ (1993). Fludarabine phosphate in the treatment of chronic lymphocytic leukemia: biology, clinical impact, and future directions. In Freireich EJ, Kantarjian H (eds), Leukemia: Advances in Research and Treatment. Boston: Kluwer Academic Publishers, pp. 105–119.
3. Brockman RW, Cheng Y, Schabel F, Montgomery J (1980). Metabolism and chemotherapeutic activity of 9-β-D-arabinofuranosyl-2-fluoroadenine against murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinase. Cancer Res 40:3610–3615.
4. Plunkett W, Huang P, Gandhi V (1990). Metabolism and action of fludarabine phosphate. Semin Oncol 17(Suppl 8):3–17.
5. Hockenberry D, Nuñez G, Milliman C, Schreiber R, Korsmeyer S (1990). Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348:334–336.